Duchenne Muscular Dystrophy (DMD) Treatment Market 2019 | Research and Development by Key Players include SUMMIT Therapeutics Plc., PTC Therapeutics, BioMarin Pharmaceuticals Incorporated, Sarepta Therapeutics, Pfizer Incorporated, Pharmacia & Upjohn LLC

According to the reports of Centers for Disease Control and prevention (CDC) 2007, 349 out of 2.37 million males in the United States were reported to be suffering from DMD. Whereas in 2019, 349 new cases of DMD were reported. Increasing incidences of DMD and requirement for its treatment is driving the growth of duchenne muscular dystrophy treatment market.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/898

Various organizations are involved in spreading awareness and investing in research and development to find the effective treatment for this disease, which is contributing to the growth of duchenne muscular dystrophy treatment market. For instance, Muscular Dystrophy Association (MDA), U.S. invests 75000 USD in research and development to find out the treatment for duchenne muscular dystrophy and the association funds more than 150 care centers, health care facility centers, and hospitals across U.S. and other countries.

Moreover, other factors, such as constant research on stem cell therapy, gene therapy, and exon skipping drugs for the treatment of DMD is expected to propel the growth of DMD treatment market. However, major restraints hampering the growth of duchenne muscular dystrophy treatment market are, low seeking rate due to prognosis and late diagnosis of this disease.

Key players operating duchenne muscular dystrophy (DMD) treatment market includes SUMMIT Therapeutics Plc., PTC Therapeutics, BioMarin Pharmaceuticals Incorporated, Sarepta Therapeutics, Pfizer Incorporated, Pharmacia & Upjohn LLC, and others.

Major industry players are involved in the research and development of novel drugs for treatment, and strategies such as collaboration and partnership are adopted by companies to hold the major share in the duchenne muscular dystrophy (DMD) treatment market.

Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/898

For instance, PTC Therapeutics International Limited has obtained conditional approval and orphan drug designation in 2014 for Translarna, which is a novel gene therapy for the treatment of duchenne muscular dystrophy.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.